People with hepatitis C who inject drugs - Underserved, not undeserving

G. J. DORE ; S. TROOSKIN | 2020
Dans New England Journal of Medicine (Vol.383, n°7, August 13, 2020) Article : Périodique

To reduce the burden of HCV, it will be important to expand harm reduction for people who inject drugs. One model comes from Australia, where high treatment uptake has reduced the prevalence of active infection in this population.

Plus d'info

Ajouter à la sélection

Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs [Commentary]

E. DAY ; T. BRODER ; J. BRUNEAU ; S. CRUSE ; M. DICKIE ; S. FISH ; C. GRILLON ; N. LUHMANN ; K. MASON ; E. MCLEAN ; S. TROOSKIN ; C. TRELOAR ; J. GREBELY | 2019
Dans International Journal of Drug Policy (Vol.66, April 2019) Article : Périodique

It is estimated that 6.1 million people with recent injecting drug use (PWID) are living with hepatitis C virus (HCV). Although HCV-related morbidity and mortality among PWID continues to increase, the advent of direct acting antiviral (DAA) HCV[...]

Plus d'info

Ajouter à la sélection